Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Hepatitis B in Patients With End-Stage Renal Disease Undergoing Maintenance Hemodialysis



Beladimousavi SS1 ; Shahbazian H1 ; Faramarzi M1 ; Khodadadi S2 ; Nasri H3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Chronic Renal Failure Research Center, Jundishapour University of Medical Sciences, Ahwaz, Iran
  2. 2. Nickan Research Institute, Isfahan, Iran
  3. 3. Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Journal of Isfahan Medical School Published:2016

Abstract

Despite all prevention methods, hepatitis B virus (HBV), which can cause acute and chronic hepatitis, cirrhosis and liver cancer, still has remained endemic in many areas and more than 350 million people are chronic carriers of this virus in the world. The incidence of hepatitis B infection has significantly decreased among the patients with end stage renal disease during the past few decades due to factors such as blood screening for HBsAg and anti-HBc, reducing the need for blood transfusion after the advent of erythropoietin, hepatitis B vaccination and the implementation of infection control measures in hemodialysis units. It seems that HBsAg test is sufficient for the diagnosis of HBV infection in most end stage renal disease (ESRD) patients. However since the biochemical tests often cannot be reliable to indicate the status of liver pathology, the liver biopsy is the best method to ascertain the activity of hepatitis and the degree of cirrhosis. It is often recommended when antiviral treatment is being considered and before kidney transplantation for assesses the activity of HBV-related liver disease. According to the side effects of interferon-alfa among dialysis patients, nucleoside analogs are better choices for the treatment of hepatitis B among these patients. Finally it should be noted that Entecavir is the recommended first-line oral medication for hepatitis B among these patients. © 2016, Isfahan University of Medical Sciences(IUMS). All rights reserved.
Other Related Docs
9. Diabetes Mellitus and Renal Failure: Prevention and Management, Journal of Research in Medical Sciences (2015)
10. World Kidney Day 2016: Awareness for Saving Kidneys, Shiraz E Medical Journal (2015)
11. Cisplatin-Induced Renal Toxicity: A Short Review, Life Science Journal (2014)
12. On the Occasion of World Hypertension Day 2016, Journal of Isfahan Medical School (2016)
18. Protective Effects of Metformin on Renal Tubular Cells, Iranian Red Crescent Medical Journal (2014)
24. Hepatitis G Virus Exposure in Dialysis Patients and Blood Donors in Isfahan-Iran, International Journal of Preventive Medicine (2014)
26. New Concepts in Nutraceuticals As Alternative for Pharmaceuticals, International Journal of Preventive Medicine (2014)
37. Occult Hepatitis B Among Iranian Hepatitis C Patients, Journal of Research in Medical Sciences (2009)
43. The Protective Effect of Garlic Extract on Diabetic Nephropathy, Journal of Isfahan Medical School (2013)
46. Effect of Vitamin D on Insulin Resistance and Nephropathy in Type 2 Diabetes, Journal of Research in Medical Sciences (2014)
49. Seroprevalence of Hepatitis B in Nahavand, Islamic Republic of Iran, Eastern Mediterranean Health Journal (2006)